Clinical trial
Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
NCT01107392 is registered in ClinicalTrials.gov with Allergan as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
- Lead sponsor
- Allergan
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 1, 2010
- Completion date
- June 8, 2012
- Enrollment
- 315 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.
benign prostatic hyperplasia